An interventional study of Pulmonary ultrasound in Congestive Heart Failure(CHF) and Pulmonary Edema, sponsored by Rutgers, The State University of New Jersey. Not yet recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-13.
Sponsored by Rutgers, The State University of New Jersey · Not applicable, Interventional, and Diagnostic
Among 2,156 studies in Heart Failure with a site in United States — 348 open to participants now, 437 under way, 27 of them phase 3. Heart Failure · United States.
Among the 2,156 studies in Heart Failure with a site in United States, this one is the 146th largest by planned enrollment of the 1,600 interventional ones, is one of 95 that started in 2026, is one of 886 with no phase, reaches primary completion later than 343 of the 436 other live ones, and was the 2,107th registered.
6,331 studies on the registry are indexed under Heart Failure; 1,396 are open to participants now.
This study's planned enrollment of 1,000 is above the median of 76 across 4,049 interventional studies indexed under Heart Failure.
Browse Heart Failure studies →348 of the 2,156 studies in Heart Failure with a site in United States are open now, in 12 countries. Each count lists the studies.
Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 64 take children under 18; 96 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →2,156 studies; the count open now beside each. This study's row is marked.
First in 1983; this study’s year is marked. 95 started in 2026.
Median enrollment 65 across the 1,600 interventional studies, 150 across the 551 observational. Of the 1,509 that completed or were terminated, 629 (42%) have results posted.
745 of 2,156 have an industry lead sponsor. The 10 most frequent:
Rutgers, The State University of New Jersey is the lead sponsor of 506 studies on the registry; 131 are open to participants now.
Of its 39 completed or terminated interventional studies of FDA-regulated products, 31 (79%) have results posted.
Rutgers, The State University of New Jersey has 2 studies filed under Heart Failure — fewer than ten, so there is no comparison to draw.
139 of the studies in Heart Failure with a site in United States that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02901184Phase 3Uppsala UniversitySpironolactone Initiation Registry Randomized Interventional Trial in Heart Failure With Preserved Ejection Fraction | 2026-12 |
| NCT06307652Phase 3AstraZenecaStudy to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function | 2027-04-16 |
| NCT06736574Phase 3CytokineticsStudy With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction | 2027-09 |
| NCT06024746Phase 3Colorado Prevention CenterA Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF) | 2027-11 |
| NCT06008197Phase 3Colorado Prevention CenterA Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients | 2027-11 |
Among the 2,156 studies in Heart Failure with a site in United States, from their registry updates:
The goal of this prospective nonrandomized study is to determine if prehospital lung ultrasound findings result in a change in patient management. This study will look at how lung ultrasound exam improves diagnosis of respiratory distress in patients being treated by Emergency Medical Services, such as patients with heart failure. Additional questions include:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
At least one of the following:
Exclusion Criteria:
Diagnostic Test: Pulmonary ultrasound
Patients who meet inclusion criteria but were treated before ultrasound was available
Patients who do not receive ultrasound after paramedic training due to factors such as lack of probe availability, clinician decision, refusal, etc. Ultrasound will not be deliberately withheld from any patient.
Ultrasound of up to six lung zones (1, 2, and 4) will be obtained. Paramedics will assess for the presence of B lines.
Frequency with which prehospital lung ultrasound findings result in a change in patient management by EMS
Frequency of management changes will be compared from before prehospital ultrasound was used to after prehospital ultrasound has been implemented.
Time frame: From time of patient encounter to patient handoff at the hospital. (anticipated average of one hour)
Survival to discharge
Time frame: At time of hospital discharge (anticipated average one week)
Percent of prehospital diagnoses agreeing with hospital diagnosis
Diagnostic accuracy
Time frame: At time of hospital discharge (anticipated average of one week)
Whether or not patient is intubated by EMS or during hospital admission, recorded as yes or no
Time frame: EMS patient encounter to hospital discharge (anticipated average one week)
Days on ventilator or non-invasive ventilation
Time frame: Hospital arrival to hospital discharge (anticipated average one week)
Length of stay
Time frame: Hospital arrival to hospital discharge (anticipated average one week)
Length of ICU stay
Time frame: Hospital admission to hospital discharge (anticipated average one week)
Paramedic ultrasound interpretation accuracy
Comparison between paramedic interpretation (of presence of lung sliding and number of B lines) with physician interpretation
Time frame: Enrollment
Quality of ultrasound obtained by paramedic
Rating of ultrasound using a five-point scale (1 being no recognizable structures, 5 being criteria met for diagnosis, all structures imaged with excellent image quality and diagnosis completely supported) by physician
Time frame: Enrollment
Plan to share: No — Data that can be linked to individual patients will not be shared due to patient confidentiality.
No publications or documents are linked to this record.
Start is estimated for Aug 2026; primary completion for Dec 2028, 28 months later.
Of 1,118 non-industry interventional studies with no phase under Heart Failure, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 50. This study's planned 28 months is close to that.
Counting every sponsor, half of 1,354 studies reached it within 31 months; a quarter within 16 and three quarters within 52.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Rutgers, The State University of New Jersey →